Authors

Latest:

Dr. Mott Discusses Targeted Therapy for ALK+ NSCLC

Frank E. Mott, MD, FACP, department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses taregeted therapy for ALK-positive non-small cell lung cancer (NSCLC).

Frank Ferrara

Latest:

Argumentum Ad Populum: Medical Wikis 101

What exactly is a medical wiki, and for that matter, a wiki in general? Are these resources useful to you and your patients?

Frank Vicini, MD

Latest:

Hypofractionated and Stereotactic Body Radiotherapy in Prostate Cancer

Despite limited data comparing stereotactic body radiation therapy to standard or hypofractionated radiotherapy with regards to long-term clinical outcomes and toxicity profiles, the data are promising and appropriately selected patients can be offered such an approach off-protocol.

Frankie Ann Holmes, MD

Latest:

Dr. Holmes on Neoadjuvant Endocrine Therapy in Breast Cancer

Frankie Ann Holmes, MD, a physician at Texas Oncology, discusses neoadjuvant endocrine therapy for patients with breast cancer.

Fred C. Kass, MD

Latest:

Dr. Kass on Optimal Treatment Sequencing in HER2-Positive Breast Cancer

Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, discusses challenges associated with optimal treatment sequencing for patients with HER2-positive breast cancer.

Fred Eberlein

Latest:

TechSectors: Connectivity: Improving Physician-Patient Communication

More than ever before, healthcare professionals are strapped for time.

Fred Hirsch, MD, PhD, University of Colorado School of Medicine

Fred R. Hirsch, MD, PhD

Latest:

Dr Hirsch on the Benefits of Tissue vs Liquid Biopsy in NSCLC

Fred R. Hirsch, MD, PhD, discusses the pros and cons of completing a tissue biopsy compared with a liquid biopsy in non–small cell lung cancer.

Fred Saad, MD

Latest:

Dr Saad on the Safety Profile of Darolutamide Plus ADT in mHSPC

Fred Saad, CQ, MD, FRCS, FCAHS, discusses the safety findings from the phase 3 ARANOTE trial investigating darolutamide plus ADT in patients with mHSPC.

Fred Saad, MD, FRCS

Latest:

Dr Saad on the Continued Investigation of Darolutamide Plus ADT in mHSPC

Fred Saad, CQ, MD, FRCS, FCAHS, discusses next steps for the investigation of darolutamide plus ADT in patients with metastatic hormone-sensitive prostate cancer.

Fred Schumacher, PhD, MPH

Latest:

Fred Schumacher on Genetic Risk Factors of Prostate Cancer

Fred Schumacher, PhD, MPH, associate professor, Case Western Reserve University, discusses a study that led to the identification of genetic risk factors of prostate cancer.

Frederic Triebel, MD, PhD

Latest:

Dr. Triebel on the Rationale for a Novel Immunotherapy Combination in Melanoma

Frederic Triebel, MD, PhD, chief scientific officer and chief medical director, Immutep Ltd, discusses the rationale for a novel immunotherapy combination in patients with unresectable or metastatic melanoma.

Frederic Zenhausern, PhD, MBA

Latest:

Platform Technology Development for Biologically Targeted Dosimetry and Radiotherapy

The ability to obtain high-quality radiobiological information about the interactions between tumor and healthy tissue, when using ionizing radiations, would contribute to the development of more effective and personalized radiotherapy treatments.

Frederick Alan Rapoport, MD

Latest:

Dr. Rapoport Describes Samsca's Mechanism of Action

Frederick Alan Rapoport, MD, clinical instructor in the Department of Medicine at NYU Langone Medical Center, describes the mechanism and utility of Samsca (tolvaptan).

Frederick L. Locke, MD, Moffitt Cancer Center

Latest:

Practice Patterns and Real Use of Epcoritamab and Glofitamab

A panel of experts discuss the role of odronextamab.

Frederick Locke, MD

Latest:

Safety Considerations for Second-line CAR T-cell Therapy in Relapsed/Refractory DLBCL

A review of studies on safety management with CAR T-cell therapy, focusing on CRS/ICANS in the relapsed/refractory setting, key takeaways from Cohorts 4 and 6, and the impact of ZUMA-24 preliminary analysis on second-line safety strategies.

Frederick Locke, MD, Moffitt Cancer Center

Freya R. Schnabel, MD

Latest:

Dr. Schnabel Discusses the DCIS Recurrence Score

Dr. Freya Schnabel from NYU School of Medicine Discusses the DCIS Recurrence Score

Funda Meric-Bernstam, MD

Latest:

Dr Meric-Bernstam on the Efficacy of T-DXd in HER2-Expressing Solid Tumors

Funda Meric-Bernstam, MD, discusses results from the phase 2 DESTINY-PanTumor02 trial of fam-trastuzumab deruxtecan-nxki in HER2-expressing solid tumors.

G. Stephen Nace, MD

Latest:

The Risk of Risk: Explaining Difficult Concepts to Patients

A key component of health literacy is the ability to understand statistics and concepts like "probability" and "risk."